402 related articles for article (PubMed ID: 26551670)
21. Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma.
Scarisbrick JJ; Whittaker S; Evans AV; Fraser-Andrews EA; Child FJ; Dean A; Russell-Jones R
Blood; 2001 Feb; 97(3):624-30. PubMed ID: 11157477
[TBL] [Abstract][Full Text] [Related]
22. Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2.
Ungewickell A; Bhaduri A; Rios E; Reuter J; Lee CS; Mah A; Zehnder A; Ohgami R; Kulkarni S; Armstrong R; Weng WK; Gratzinger D; Tavallaee M; Rook A; Snyder M; Kim Y; Khavari PA
Nat Genet; 2015 Sep; 47(9):1056-60. PubMed ID: 26258847
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA profiling reveals that miR-21, miR486 and miR-214 are upregulated and involved in cell survival in Sézary syndrome.
Narducci MG; Arcelli D; Picchio MC; Lazzeri C; Pagani E; Sampogna F; Scala E; Fadda P; Cristofoletti C; Facchiano A; Frontani M; Monopoli A; Ferracin M; Negrini M; Lombardo GA; Caprini E; Russo G
Cell Death Dis; 2011 Apr; 2(4):e151. PubMed ID: 21525938
[TBL] [Abstract][Full Text] [Related]
24. Sézary syndrome originates from heavily mutated hematopoietic progenitors.
Harro CM; Sprenger KB; Chaurio RA; Powers JJ; Innamarato P; Anadon CM; Zhang Y; Biswas S; Mandal G; Mine JA; Cortina C; Nagy MZ; Martin AL; Handley KF; Borjas GJ; Chen PL; Pinilla-Ibarz J; Sokol L; Yu X; Conejo-Garcia JR
Blood Adv; 2023 Sep; 7(18):5586-5602. PubMed ID: 37531660
[TBL] [Abstract][Full Text] [Related]
25. FOXP3+CD25- tumor cells with regulatory function in Sézary syndrome.
Heid JB; Schmidt A; Oberle N; Goerdt S; Krammer PH; Suri-Payer E; Klemke CD
J Invest Dermatol; 2009 Dec; 129(12):2875-85. PubMed ID: 19626037
[TBL] [Abstract][Full Text] [Related]
26. Mogamulizumab induces long-term immune restoration and reshapes tumour heterogeneity in Sézary syndrome.
Roelens M; de Masson A; Andrillon A; Ram-Wolff C; Biard L; Boisson M; Mourah S; Battistella M; Toubert A; Bagot M; Moins-Teisserenc H
Br J Dermatol; 2022 Jun; 186(6):1010-1025. PubMed ID: 35041763
[TBL] [Abstract][Full Text] [Related]
27. The role of 9-O-acetylated ganglioside D3 (CD60) and {alpha}4{beta}1 (CD49d) expression in predicting the survival of patients with Sezary syndrome.
Scala E; Abeni D; Pomponi D; Narducci MG; Lombardo GA; Mari A; Frontani M; Picchio MC; Pilla MA; Caprini E; Russo G
Haematologica; 2010 Nov; 95(11):1905-12. PubMed ID: 20663947
[TBL] [Abstract][Full Text] [Related]
28. Novel and highly recurrent chromosomal alterations in Sézary syndrome.
Vermeer MH; van Doorn R; Dijkman R; Mao X; Whittaker S; van Voorst Vader PC; Gerritsen MJ; Geerts ML; Gellrich S; Söderberg O; Leuchowius KJ; Landegren U; Out-Luiting JJ; Knijnenburg J; Ijszenga M; Szuhai K; Willemze R; Tensen CP
Cancer Res; 2008 Apr; 68(8):2689-98. PubMed ID: 18413736
[TBL] [Abstract][Full Text] [Related]
29. EPHA4 is overexpressed but not functionally active in Sézary syndrome.
Hameetman L; van der Fits L; Zoutman WH; Out-Luiting JJ; Siegal G; de Esch IJ; Vermeer MH; Tensen CP
Oncotarget; 2015 Oct; 6(31):31868-76. PubMed ID: 26376612
[TBL] [Abstract][Full Text] [Related]
30. NOTCH1 signaling as a therapeutic target in Sézary syndrome.
van der Fits L; Qin Y; Out-Luiting JJ; Vermeer KG; Whittaker S; van Es JH; Tensen CP; Vermeer MH
J Invest Dermatol; 2012 Dec; 132(12):2810-7. PubMed ID: 22718117
[TBL] [Abstract][Full Text] [Related]
31. Increased Expression of PLS3 Correlates with Better Outcome in Sézary Syndrome.
Boonk SE; Zoutman WH; Putter H; Ram-Wolff C; Felcht M; Klemke CD; Ranki A; Quaglino P; Whittaker S; Bagot M; Willemze R; Vermeer MH
J Invest Dermatol; 2017 Mar; 137(3):754-757. PubMed ID: 27984038
[No Abstract] [Full Text] [Related]
32. Candidate driver genes involved in genome maintenance and DNA repair in Sézary syndrome.
Woollard WJ; Pullabhatla V; Lorenc A; Patel VM; Butler RM; Bayega A; Begum N; Bakr F; Dedhia K; Fisher J; Aguilar-Duran S; Flanagan C; Ghasemi AA; Hoffmann RM; Castillo-Mosquera N; Nuttall EA; Paul A; Roberts CA; Solomonidis EG; Tarrant R; Yoxall A; Beyers CZ; Ferreira S; Tosi I; Simpson MA; de Rinaldis E; Mitchell TJ; Whittaker SJ
Blood; 2016 Jun; 127(26):3387-97. PubMed ID: 27121473
[TBL] [Abstract][Full Text] [Related]
33. Histopathological and immunophenotypical criteria for the diagnosis of Sézary syndrome in differentiation from other erythrodermic skin diseases: a European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force Study of 97 cases.
Klemke CD; Booken N; Weiss C; Nicolay JP; Goerdt S; Felcht M; Géraud C; Kempf W; Assaf C; Ortonne N; Battistella M; Bagot M; Knobler R; Quaglino P; Arheiliger B; Santucci M; Jansen P; Vermeer MH; Willemze R
Br J Dermatol; 2015 Jul; 173(1):93-105. PubMed ID: 25864856
[TBL] [Abstract][Full Text] [Related]
34. Sézary Syndrome in a 17-Year-Old Boy: Clinicopathologic Features and Genomic Profile.
Alberti-Violetti S; Vezzoli P; Corti L; Fanoni D; Merlo V; Venegoni L; Reseghetti A; Berti E
Pediatr Dermatol; 2016 Sep; 33(5):e318-21. PubMed ID: 27397596
[TBL] [Abstract][Full Text] [Related]
35. Contribution of STAT3 and RAD23B in Primary Sézary Cells to Histone Deacetylase Inhibitor FK228 Resistance.
Butler RM; McKenzie RC; Jones CL; Flanagan CE; Woollard WJ; Demontis M; Ferreira S; Tosi I; John S; Whittaker SJ; Mitchell TJ
J Invest Dermatol; 2019 Sep; 139(9):1975-1984.e2. PubMed ID: 30910759
[TBL] [Abstract][Full Text] [Related]
36. Sézary T-cell-activating factor induces functional interleukin 2 receptors on T-cells derived from patients with Sézary syndrome.
Abrams JT; Ghosh SK; DeFreitas E
Cancer Res; 1993 Nov; 53(22):5501-6. PubMed ID: 8221690
[TBL] [Abstract][Full Text] [Related]
37. Blood and skin-derived Sezary cells: differences in proliferation-index, activation of PI3K/AKT/mTORC1 pathway and its prognostic relevance.
Cristofoletti C; Bresin A; Picozza M; Picchio MC; Monzo F; Helmer Citterich M; Passarelli F; Frezzolini A; Scala E; Monopoli A; Cantonetti M; Benucci R; D'Atri S; Caprini E; Russo G; Narducci MG
Leukemia; 2019 May; 33(5):1231-1242. PubMed ID: 30518812
[TBL] [Abstract][Full Text] [Related]
38. Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome.
van Doorn R; van Kester MS; Dijkman R; Vermeer MH; Mulder AA; Szuhai K; Knijnenburg J; Boer JM; Willemze R; Tensen CP
Blood; 2009 Jan; 113(1):127-36. PubMed ID: 18832135
[TBL] [Abstract][Full Text] [Related]
39. Mycosis fungoides exhibits a Th1-type cell-mediated cytokine profile whereas Sezary syndrome expresses a Th2-type profile.
Saed G; Fivenson DP; Naidu Y; Nickoloff BJ
J Invest Dermatol; 1994 Jul; 103(1):29-33. PubMed ID: 8027577
[TBL] [Abstract][Full Text] [Related]
40. The molecular pathogenesis of mycosis fungoides and Sézary syndrome.
Döbbeling U
G Ital Dermatol Venereol; 2008 Dec; 143(6):385-94. PubMed ID: 19169211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
